SynapDx Corp. said Monday that it has named Kevin Hrusovsky its board of directors. Previously, Hrusovsky served as president of life sciences and technology at PerkinElmer. Based in Lexington, Mass., SynapDx is a provider of diagnostic services for autism and neurodevelopmental disorders. It is backed by North Bridge Venture Partners, General Catalyst Partners, Google Ventures, Foundation Medical Partners, LabCorp, The Kraft Group, Casdin Capital and Windham Venture Partners.
LEXINGTON, Mass.–(BUSINESS WIRE)–SynapDx Corporation, a diagnostic company developing an innovative blood test for the early detection of autism spectrum disorders, today announced that Kevin Hrusovsky has been appointed to its Board of Directors. Hrusovsky, former president of Life Sciences and Technology at PerkinElmer, has a breadth of experience in launching technologies and building fast-growing companies in the life science industry.
“We are excited to welcome Kevin to our board,” said Stan Lapidus, CEO and founder, SynapDx. “He brings with him a wealth of expertise and leadership in building great companies and developing successful commercialization strategies.”
Hrusovsky previously served as CEO of Caliper Life Sciences (CALP) from 2003 until the company was acquired by PerkinElmer in 2011 for $650m cash. Hrusovsky was responsible for growing Caliper into a leader in molecular diagnostic and imaging technologies, increasing the valuation of the company tenfold between 2009 and 2011. Prior to Caliper, Hrusovsky was president and CEO of Zymark Corporation, transforming the company into a premier technology provider in laboratory automation.
“I look forward to working with this highly experienced team in such an important area of healthcare,” said Hrusovsky. “SynapDx’s novel bioinformatics and sequencing platform has the potential to transform the lives of children and their families through the early detection of autism and a broader panel of disorders over time.”
Hrusovsky’s current and past board seats include 908 Devices, Solect, SeraCare (SRLS), Xenogen (XGEN), Caliper Life Sciences (CALP), Alliant Medical Technologies (AMT), the Center for Biomedical Engineering at Brown University, the Strategy Committee of Boston Children’s Hospital and the Society of Laboratory Automation. Earlier in his career, Kevin held general management positions at FMC Corporation and E.I. DuPont de Nemours. Kevin holds a B.S. in Mechanical Engineering from the Ohio State University and an MBA from Ohio University.
About SynapDx Corp.
SynapDx is a private company developing laboratory diagnostic services for autism and neurodevelopmental disorders, with the initial goal of enabling earlier detection of autism spectrum disorders (ASDs). The company collaborates with ASD experts at leading institutions. SynapDx was founded in 2010 and is based in Lexington, Mass. Members of the board of directors are: Stan Lapidus, CEO SynapDx; Hemant Taneja, Partner at General Catalyst; Bob Carpenter, former Lead Director of Genzyme and founder of Integrated Genetics; Tom Mac Mahon, founding and former CEO of LabCorp; Andy Conrad, Google; Bill Geary, Partner at North Bridge Venture Partners. SynapDx’s investors include North Bridge Venture Partners, General Catalyst Partners, Google Ventures, Foundation Medical Partners, LabCorp, The Kraft Group, Casdin Capital and Windham Venture Partners.